Brokerages Set Vericel (VCEL) Price Target at $14.00

Vericel (NASDAQ:VCEL) has earned an average rating of “Buy” from the seven research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $14.25.

A number of research analysts have issued reports on the stock. BTIG Research reissued a “buy” rating and set a $13.00 target price (up from $8.00) on shares of Vericel in a research note on Monday, March 5th. ValuEngine raised shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Piper Jaffray reissued an “overweight” rating and set a $9.00 target price on shares of Vericel in a research note on Tuesday, January 2nd. BidaskClub raised shares of Vericel from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, March 7th. Finally, Leerink Swann initiated coverage on shares of Vericel in a research note on Wednesday. They set an “outperform” rating and a $15.00 target price for the company.

How to Become a New Pot Stock Millionaire

Several hedge funds have recently added to or reduced their stakes in VCEL. Goldman Sachs Group Inc. bought a new stake in shares of Vericel during the 4th quarter worth about $105,000. Bank of Montreal Can bought a new stake in shares of Vericel during the 4th quarter worth about $140,000. Wells Fargo & Company MN raised its position in shares of Vericel by 1,374.2% during the 4th quarter. Wells Fargo & Company MN now owns 30,029 shares of the biotechnology company’s stock worth $163,000 after buying an additional 27,992 shares in the last quarter. Citadel Advisors LLC bought a new stake in shares of Vericel during the 3rd quarter worth about $235,000. Finally, Bank of New York Mellon Corp raised its position in shares of Vericel by 35.2% during the 4th quarter. Bank of New York Mellon Corp now owns 44,188 shares of the biotechnology company’s stock worth $241,000 after buying an additional 11,509 shares in the last quarter. Institutional investors own 37.22% of the company’s stock.

Vericel stock traded up $0.10 during midday trading on Friday, reaching $11.15. 1,012,412 shares of the stock traded hands, compared to its average volume of 1,039,468. The company has a quick ratio of 3.57, a current ratio of 3.86 and a debt-to-equity ratio of 0.75. The firm has a market capitalization of $406.30, a price-to-earnings ratio of -23.00 and a beta of 3.18. Vericel has a fifty-two week low of $2.35 and a fifty-two week high of $12.80.

Vericel (NASDAQ:VCEL) last posted its earnings results on Monday, March 5th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.13. The firm had revenue of $23.35 million during the quarter. Vericel had a negative net margin of 27.04% and a negative return on equity of 98.77%. research analysts expect that Vericel will post -0.24 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was published by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3335959/brokerages-set-vericel-vcel-price-target-at-14-00.html.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States.

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$1.52 EPS Expected for BOK Financial Co.  This Quarter
$1.52 EPS Expected for BOK Financial Co. This Quarter
Shore Bancshares  Given Daily Media Sentiment Rating of 0.38
Shore Bancshares Given Daily Media Sentiment Rating of 0.38
Lifetime Brands  Given Daily Media Sentiment Score of 0.15
Lifetime Brands Given Daily Media Sentiment Score of 0.15
Bel Fuse  Receiving Somewhat Favorable News Coverage, Analysis Finds
Bel Fuse Receiving Somewhat Favorable News Coverage, Analysis Finds
Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Investar  Share Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Investar Share Price
Novozymes  & Its Competitors Head-To-Head Analysis
Novozymes & Its Competitors Head-To-Head Analysis


Leave a Reply

© 2006-2018 Ticker Report. Google+.